# Attovia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/attovia-therapeutics

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.attovia.com
- Total disclosed funding: $173M
- Latest round: Series C (Apr 15, 2025)
- Investors on record: 14

## About

Founded in 2023 and based in California, US, Attovia Therapeutics, Inc. operates as a biotechnology company that develops biotherapeutics for the treatment of immune-mediated disease and cancer.

Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages Attobody™, Alamar Biosciences’ novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization, and fast tissue penetration. Attovia’s lead program is an Attobody to treat immune disease. The company is currently progressing multiple programs and plans to initiate additional discovery projects.

The company will use the funding to support the development of its platform called Attobody and its clinical concept.

## Funding rounds

- Series C, Apr 15, 2025, $90M — Frazier Healthcare Partners, Marshall Wace, Nextech, Goldman Sachs, Sanofi Ventures, VenBio, EcoR1 Capital, Cormorant Asset Management, Illumina Ventures, Vida Ventures, Deep Track Capital, Mirae Asset Capital Life Science
- Series B, May 1, 2024, $53M — Frazier Healthcare Partners, Marshall Wace, Nextech, Redmile Group, VenBio, EcoR1 Capital, Cormorant Asset Management, Illumina Ventures, Goldman Sachs, Logos Capital
- Series A, Jun 1, 2023, $30M — Frazier Healthcare Partners, VenBio, Illumina Ventures

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B, Series C
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A, Series B, Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Goldman Sachs — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series C
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C
- Mirae Asset Capital Life Science (https://capitalatlas.ai/funds/mirae-asset-capital-life-science) — Series C